← ANALYST RATINGS · TIPRANKS
Definium Therapeutics (DFTX): analyst forecast and price target
Price targets and ratings of
Analyst consensus
Strong Buy16 Buy0 Hold0 Sell
Ratings of 16 analysts in the last 3 months12-month forecast
$72.75+126.6% upside
Based on 16 price targets given in the last 3 months, the average target is $72.75, the highest $91.00, the lowest $53.00. The average is +126.6% from the last price of $32.10.
Highest target $91.00
Average target $72.75
Lowest target $53.00
Analyst ratings 18
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $36.00 → $34.00−5.6% | Hold | +5.9% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $35.00 → $33.00−5.7% | Hold | +2.8% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $35.00 → $33.00−5.7% | Hold | +2.8% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $35.00 → $33.00−5.7% | Hold | +2.8% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $37.00 → $35.00−5.4% | Hold | +9.0% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $33.00 → $31.00−6.1% | Hold | −3.4% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $37.00 → $36.00−2.7% | Hold | +12.1% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $36.00 → $35.00−2.8% | Hold | +9.0% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $36.00 → $35.00−2.8% | Hold | +9.0% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $36.00 → $35.00−2.8% | Hold | +9.0% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $38.00 → $37.00−2.6% | Hold | +15.3% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $34.00 → $33.00−2.9% | Hold | +2.8% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $36.00 → $37.00+2.8% | Hold | +15.3% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $35.00 → $36.00+2.9% | Hold | +12.1% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $35.00 → $36.00+2.9% | Hold | +12.1% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $35.00 → $36.00+2.9% | Hold | +12.1% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $37.00 → $38.00+2.7% | Hold | +18.4% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $33.00 → $34.00+3.0% | Hold | +5.9% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $37.00 → $36.00−2.7% | Hold | +12.1% | Reiterated | 09.10.26on TipRanks 11:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $36.00 → $35.00−2.8% | Hold | +9.0% | Reiterated | 09.10.26on TipRanks 11:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $36.00 → $35.00−2.8% | Hold | +9.0% | Reiterated | 09.10.26on TipRanks 11:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $36.00 → $35.00−2.8% | Hold | +9.0% | Reiterated | 09.10.26on TipRanks 11:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $38.00 → $37.00−2.6% | Hold | +15.3% | Reiterated | 09.10.26on TipRanks 11:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $34.00 → $33.00−2.9% | Hold | +2.8% | Reiterated | 09.10.26on TipRanks 11:05 | — | |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $84.00 | Buy | +161.7% | Initiated | 09.10.26on TipRanks 07:10 | +7.4%next day −4.5% · 5 days −11.0% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $37.00 → $36.00−2.7% | Hold | +12.1% | Reiterated | 08.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $37.00 → $36.00−2.7% | Hold | +12.1% | Reiterated | 08.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $39.00 → $38.00−2.6% | Hold | +18.4% | Reiterated | 08.10.26on TipRanks 05:05 | — | |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $91.00 | Buy | +183.5% | Reiterated | 07.10.26on TipRanks 05:45 | −1.2%next day −2.2% · 5 days −1.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $38.00 → $37.00−2.6% | Hold | +15.3% | Reiterated | 07.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $37.00 → $36.00−2.7% | Hold | +12.1% | Reiterated | 07.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $35.00 → $34.00−2.9% | Hold | +5.9% | Reiterated | 07.10.26on TipRanks 03:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $38.00 | Hold | +18.4% | Reiterated | 28.09.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $37.00 | Hold | +15.3% | Reiterated | 28.09.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $37.00 | Hold | +15.3% | Reiterated | 28.09.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $37.00 | Hold | +15.3% | Reiterated | 28.09.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $39.00 | Hold | +21.5% | Reiterated | 28.09.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $35.00 | Hold | +9.0% | Reiterated | 28.09.26on TipRanks 17:05 | — | |
| Francois Brisebois★★★★★★★★★★#2595 · hits 43% · avg +5.9% | LifeSci Capital | $78.00 | Buy | +143.0% | Reiterated | 19.09.26on TipRanks 10:30 | −0.3%next day +2.7% · 5 days −1.2% | ↗ |
| Michael Okunewitch★★★★★★★★★★#11525 · hits 36% · avg −3.3% | Maxim Group | $55.00 | Buy | +71.3% | Reiterated | 15.09.26on TipRanks Sep 16 07:55 | −8.1%next day +3.2% · 5 days +7.1% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $60.00 → $67.00+11.7% | Buy | +108.7% | Reiterated | 15.09.26on TipRanks 22:05 | +3.2%next day +1.1% · 5 days −2.6% | ↗ |
| Justin Walsh★★★★★★★★★★#640 · hits 39% · avg +20.6% | JonesTrading | $90.00 | Buy | +180.4% | Reiterated | 15.09.26on TipRanks 10:50 | −8.1%next day +3.2% · 5 days +7.1% | ↗ |
| Sumant Kulkarni★★★★★★★★★★#670 · hits 50% · avg +14.2% | Canaccord Genuity | $64.00 → $78.00+21.9% | Buy | +143.0% | Reiterated | 15.09.26on TipRanks 07:50 | −8.1%next day +3.2% · 5 days +7.1% | ↗ |
| Christopher Chen★★★★★★★★★★#5006 · hits 100% · avg +66.9% | Robert W. Baird | $75.00 → $79.00+5.3% | Buy | +146.1% | Reiterated | 15.09.26on TipRanks 07:10 | −8.1%next day +3.2% · 5 days +7.1% | ↗ |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $70.00 | Buy | +118.1% | Reiterated | 15.09.26on TipRanks Sep 14 10:30 | +3.9%next day −8.1% · 5 days −4.3% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $70.00 → $75.00+7.1% | Buy | +133.6% | Reiterated | 14.09.26on TipRanks 16:05 | −8.1%next day +3.2% · 5 days +7.1% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $75.00 → $91.00+21.3% | Buy | +183.5% | Reiterated | 14.09.26on TipRanks 12:35 | +3.9%next day −8.1% · 5 days −4.3% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $66.00 | Buy | +105.6% | Reiterated | 14.09.26on TipRanks 08:55 | +3.9%next day −8.1% · 5 days −4.3% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $66.00 | Buy | +105.6% | Reiterated | 11.09.26on TipRanks 07:35 | +2.2%next day +3.9% · 5 days −0.1% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $72.00 | Buy | +124.3% | Reiterated | 31.08.26on TipRanks 09:45 | −2.8%next day −2.4% · 5 days −3.6% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $75.00 | Buy | +133.6% | Reiterated | 17.08.26on TipRanks 07:37 | +6.6%next day +2.7% · 5 days −3.2% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $65.00 | Buy | +102.5% | Reiterated | 13.08.26on TipRanks 10:45 | +1.9%next day −2.7% · 5 days +5.4% | ↗ |
| Unknown Analyst | Evercore ISI | $53.00 | Buy | +65.1% | Reiterated | 10.08.26on TipRanks 12:45 | −2.1%next day −9.1% · 5 days +0.3% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $25.00 | Buy | −22.1% | Initiated | 23.02.26on TipRanks Feb 24 02:10 | 0.0%next day +2.2% · 5 days +0.8% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Definium Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $72.00 at a price of $38.06 (+89.2%); now: $72.75 at $32.10 (+126.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 31 | 36 | 22 | 23 | 27 | 27 |
| Buy | 4 | 11 | 9 | 20 | 14 | 12 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.56 (from $-0.70 to $-0.45). Last quarter: $-1.44.
Best top-analyst consensus in the sector · Healthcare
About Definium Therapeutics
- CEO: Robert Barrow
- Employees: 106
- One World Trade Center, New York, NY, 10007, US
- definiumtx.com
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Data from the stock’s TipRanks forecast page, read 61 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗